Evidence-Based Recommendations for Cholesterol Management to Lower Cardiovascular Risk

The guideline governing the management of blood cholesterol to reduce cardiovascular risk was revised at the end of 2018. At that time, several critical changes were made to the guideline, including the identification of high-risk and very high-risk factors, restructuring of patient groups in which to consider drug therapy, revised therapeutic targets, and incorporation of select non-statin drugs to the clinical armamentarium. Furthermore, two additional non-statin products have come to market since the guideline’s publication. It is imperative to disseminate these updates to healthcare practitioners, so that they can provide evidence-based, patient-centered care as members of an interdisciplinary team.